BCEL Stock Overview
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$2.49|
|52 Week High||US$7.00|
|52 Week Low||US$1.51|
|1 Month Change||20.87%|
|3 Month Change||42.29%|
|1 Year Change||-57.65%|
|3 Year Change||-87.91%|
|5 Year Change||n/a|
|Change since IPO||-86.21%|
Recent News & Updates
Atreca GAAP EPS of -$0.72 misses by $0.02
Atreca press release (NASDAQ:BCEL): Q2 GAAP EPS of -$0.72 misses by $0.02. cash and cash equivalents and investments totaled $101.7 million.
Here's Why We're A Bit Worried About Atreca's (NASDAQ:BCEL) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
|BCEL||US Biotechs||US Market|
Return vs Industry: BCEL underperformed the US Biotechs industry which returned -19.6% over the past year.
Return vs Market: BCEL underperformed the US Market which returned -9.6% over the past year.
|BCEL Average Weekly Movement||16.0%|
|Biotechs Industry Average Movement||12.5%|
|Market Average Movement||7.6%|
|10% most volatile stocks in US Market||16.8%|
|10% least volatile stocks in US Market||3.1%|
Stable Share Price: BCEL is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 16% a week.
Volatility Over Time: BCEL's weekly volatility has decreased from 33% to 16% over the past year, but is still higher than 75% of US stocks.
About the Company
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company’s ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients.
Atreca Fundamentals Summary
|BCEL fundamental statistics|
Is BCEL overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|BCEL income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-2.84|
|Net Profit Margin||0.00%|
How did BCEL perform over the long term?See historical performance and comparison
Is BCEL undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for BCEL?
Other financial metrics that can be useful for relative valuation.
|What is BCEL's n/a Ratio?|
Price to Book Ratio vs Peers
How does BCEL's PB Ratio compare to its peers?
|BCEL PB Ratio vs Peers|
|Company||PB||Estimated Growth||Market Cap|
ANVS Annovis Bio
AQB AquaBounty Technologies
Price-To-Book vs Peers: BCEL is good value based on its Price-To-Book Ratio (0.8x) compared to the peer average (1.6x).
Price to Earnings Ratio vs Industry
How does BCEL's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Book vs Industry: BCEL is good value based on its Price-To-Book Ratio (0.8x) compared to the US Biotechs industry average (2x)
Price to Book Ratio vs Fair Ratio
What is BCEL's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PB Ratio||0.8x|
|Fair PB Ratio||n/a|
Price-To-Book vs Fair Ratio: Insufficient data to calculate BCEL's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of BCEL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate BCEL's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate BCEL's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
How is Atreca forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BCEL is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: BCEL is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: BCEL is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: BCEL is forecast to have no revenue next year.
High Growth Revenue: BCEL is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if BCEL's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Atreca performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BCEL is currently unprofitable.
Growing Profit Margin: BCEL is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: BCEL is unprofitable, and losses have increased over the past 5 years at a rate of 26.8% per year.
Accelerating Growth: Unable to compare BCEL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BCEL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (24.5%).
Return on Equity
High ROE: BCEL has a negative Return on Equity (-95.16%), as it is currently unprofitable.
Discover strong past performing companies
How is Atreca's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: BCEL's short term assets ($109.6M) exceed its short term liabilities ($13.5M).
Long Term Liabilities: BCEL's short term assets ($109.6M) exceed its long term liabilities ($62.2M).
Debt to Equity History and Analysis
Debt Level: BCEL is debt free.
Reducing Debt: BCEL has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BCEL has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: BCEL has less than a year of cash runway if free cash flow continues to reduce at historical rates of 24.6% each year
Discover healthy companies
What is Atreca current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BCEL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BCEL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BCEL's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BCEL's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as BCEL has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
John Orwin (57 yo)
Mr. John A. Orwin has been President, Chief Executive Officer and Director at Atreca, Inc. since April 19, 2018. Mr. Orwin has been a Director of Seagen Inc. since January 13, 2014. Prior to joining Atreca...
CEO Compensation Analysis
Compensation vs Market: John's total compensation ($USD4.19M) is above average for companies of similar size in the US market ($USD759.98K).
Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.
Experienced Management: BCEL's management team is considered experienced (3.2 years average tenure).
Experienced Board: BCEL's board of directors are considered experienced (5.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.6%.
Atreca, Inc.'s employee growth, exchange listings and data sources
- Name: Atreca, Inc.
- Ticker: BCEL
- Exchange: NasdaqGS
- Founded: 2010
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$96.093m
- Shares outstanding: 38.59m
- Website: https://www.atreca.com
Number of Employees
- Atreca, Inc.
- 835 Industrial Road
- Suite 400
- South San Francisco
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/16 00:00|
|End of Day Share Price||2022/08/16 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.